市場調查報告書

男性性腺功能低下症的全球市場:成長,趨勢,預測(2020年∼2025年)

Male Hypogonadism Market - Growth, Trends And Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 928005
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
男性性腺功能低下症的全球市場:成長,趨勢,預測(2020年∼2025年) Male Hypogonadism Market - Growth, Trends And Forecast (2020 - 2025)
出版日期: 2020年03月01日內容資訊: 英文 115 Pages
簡介

男性性腺功能低下症市場在預測期間內預計將以5.1%的年複合成長率發展。性腺功能降低症,在任何年齡都有發生的可能性,結果取決於什麼時候發病。成人男性,從睪固酮缺乏症的發病數周以內開始有症狀。性腺功能降低症,可能提高第二型糖尿病、心血管疾病、高齡男性的早死、代謝症候群、阿茲海默症的風險。

本報告提供全球男性性腺功能低下症市場調查,市場概要,各治療類型、疾病類型、地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 全球病例的增加
    • 治療的技術進步
    • 治療相關個人間的認識的不斷提升
  • 阻礙市場要素
    • 治療伴隨的高的副作用
  • 波特的五力分析

第5章 市場細分化

  • 各治療類型
    • 睪酮(睪丸激素)替代療法
    • 促性腺激素分泌補充療法
  • 各疾病類型
    • 卡門氏症候群
    • 柯林菲特氏症
    • 下垂體疾病
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Endo International Plc
    • AbbVie Inc
    • Pfizer Inc
    • Allergan Plc
    • Teva Pharmaceutical Industries Ltd
    • Eli Lilly and Company
    • Bayer AG
    • Merck & Co., Inc
    • Sun Pharmaceutical Industries Limited
    • Ferring Holding SA

第7章 市場機會及未來趨勢

目錄
Product Code: 68333

The Male Hypogonadism Market is expected to register a CAGR of 5.1% during the forecast period. Male hypogonadism or testosterone deficiency is a condition in which the body doesn't produce enough of the hormone that plays a key role in development and masculine growth during puberty or enough sperm or both. Hypogonadism may occur at any age, and the consequences differ, according to when it starts. In adult men, within a few weeks of the onset of testosterone deficiency symptoms begin. Hypogonadism may increase the risk for type 2 diabetes, cardiovascular disease, premature death in older men, metabolic syndrome, and Alzheimer's disease.

According to Boston University School of Medicine, approximately 4 to 5 million men in the United States, are affected with hypogonadism and low testosterone levels are commonly seen in older males. More than 60% of men over 65 years of age have free testosterone levels below the normal values of men between 30 to 35 years of age. A Study published in the Indian Journal of Endocrinology and Metabolism in the year 2017, estimates that prevalence of hypogonadism in type 2 diabetes patients was found to be 20.7%. Furthermore, the prevalence rate of hypogonadism in patients with type 2 diabetes was moderate with highest number of patients belonging to age group 50-59 year.

Increase in incidence and prevalence of hypogonadism, technological advancements in male hypogonadism therapy and rise in awareness about hypogonadism and its treatment option are the key driving factors in male hypogonadism market.

Key Market Trends

Gonadotropin-Releasing Hormones Therapy Segment is Expected to Hold a Major Market Share in the Male Hypogonadism Market

  • Gonadotropin releasing hormone stimulates to release follicle-stimulating hormone, and luteinizing hormone, which helps in regulating the gametogenic and steroidogenic functions of the gonads in males.
  • As per European Association of Urology 2016 report, incidence of hypogonadism in middle-aged men, varied from 2.1% to 12.8%, men aged 40-79 varied form 2.1% to 5.7%, in Europe. In addition, hypogonadism is more prevalent in older men with obesity and in men with a poor health status.
  • Gonadotropin-releasing hormones therapy segment holds a significant market share in male hypogonadism market and is anticipated to show similar trend over the forecast period. Moreover, due to rise in adoption of this therapy with increasing cases of hypogonadism in men are the key driving factors in the Gonadotropin-releasing hormones therapy segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global male hypogonadism market due to increasing incidence and prevalence of hypogonadism and rise in awareness about hypogonadism and its treatment option in this region. According to the study published in European Association of Urology Journal in the year 2017, testosterone prescription trends in the United States estimated an increase between 1.8 and 4-fold over the last two decades (1997 - 2017). Furthermore, increasing research and development coupled with technologically advanced products and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Male Hypogonadism Market is fragmented competitive and consists of a several major players. Some of the players in the market focus on technologically and innovation of advanced products to meet the growing demand of the product. Some of the companies which are currently dominating the market are Endo International Plc, AbbVie Inc, Pfizer Inc, Allergan Plc, Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Bayer AG, Merck & Co., Inc, Sun Pharmaceutical Industries Limited and Ferring Holding S.A.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Cases of Male Hypogonadism Worldwide
    • 4.2.2 Technological Advancements in Male Hypogonadism Therapy
    • 4.2.3 Growing Awareness Among Individuals Regarding Hypogonadism Treatment
  • 4.3 Market Restraints
    • 4.3.1 High Side Effects Associated with Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapy Type
    • 5.1.1 Testosterone Replacement Therapy
    • 5.1.2 Gonadotropin-Releasing Hormones Therapy
      • 5.1.2.1 Human Chorionic Gonadotropin (hCG)
      • 5.1.2.2 Follicle-stimulating Hormone (FSH)
      • 5.1.2.3 Gonadotropin-releasing Hormone (GnRH)
      • 5.1.2.4 Other Gonadotropin Replacement Therapies
  • 5.2 By Application
    • 5.2.1 Kallmann Syndrome
    • 5.2.2 Klinefelters Syndrome
    • 5.2.3 Pituitary Disorders
    • 5.2.4 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Endo International Plc
    • 6.1.2 AbbVie Inc
    • 6.1.3 Pfizer Inc
    • 6.1.4 Allergan Plc
    • 6.1.5 Teva Pharmaceutical Industries Ltd
    • 6.1.6 Eli Lilly and Company
    • 6.1.7 Bayer AG
    • 6.1.8 Merck & Co., Inc
    • 6.1.9 Sun Pharmaceutical Industries Limited
    • 6.1.10 Ferring Holding S.A

7 MARKET OPPORTUNITIES AND FUTURE TRENDS